Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1B | O75688 | 2/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.33 |
| ▸ | PPP1CC | P36873 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GMNN | O75496 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14156828 | 1.00 | PPM1B (0.33) | PPM1BPTPN1PPP1CCLMNAKDM4E | |
| SCHEMBL9853615 | 1.00 | PPM1B (0.33) | PPM1BPTPN1PPP1CCLMNAKDM4E | |
| SCHEMBL8191573 | 0.91 | — | — | |
| SCHEMBL14183600 | 0.90 | PPM1B (0.31) | PPM1BPTPN1PPP1CC | |
| SCHEMBL13954797 | 0.89 | PTGS1 (0.30) | — | |
| SCHEMBL14154776 | 0.89 | PTGS1 (0.30) | — | |
| SCHEMBL195745 | 0.87 | TSHR (0.35) | PPM1BPTPN1PPP1CCTP53TSHR | |
| SCHEMBL13935601 | 0.87 | — | — | |
| SCHEMBL17012024 | 0.84 | PPM1B (0.35) | PPM1BPTPN1PPP1CCLMNAKDM4E | |
| SCHEMBL21919183 | 0.84 | PPM1B (0.35) | PPM1BPTPN1PPP1CCLMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090041945-A1 | ACTIVE RAY CURABLE COMPOSITION, POLYMERIZATION METHOD, ACTIVE RAY CURABLE INK, IMAGE FORMING METHOD, AND INK-JET RECORDING APPARATUS | KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) | 2009-02-12 | — | — | US | disclosed |
| US-7390840-B2 | Active ray curable composition, active ray curable ink, image forming method and inkjet recording apparatus utilizing the same | KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) | 2008-06-24 | — | — | US | disclosed |
| EP-1840148-A1 | POLYMERIZABLE ACTINIC RADIATION CURABLE COMPOSITION, POLYMERIZATION METHOD, ACTINIC RADIATION CURABLE INK AND IMAGE FORMATION METHOD, AND INK JET RECORDING APPARATUS AND EPOXY COMPOUND | Konica Minolta Medical & Graphic, Inc. (JP) | 2007-10-03 | — | — | EP | disclosed |
| EP-1837357-A1 | ACTINIC RAY CURABLE COMPOSITION, ACTINIC RAY CURABLE INK, METHOD OF IMAGE FORMING THEREWITH, INKJET RECORDING APPARATUS AND EPOXY COMPOUND | Konica Minolta Medical & Graphic, Inc. (JP) | 2007-09-26 | — | — | EP | disclosed |
| EP-0421611-A1 | Method for selective plugging of a zone in a well | CONOCO INC. (US) | 1991-04-10 | — | — | EP | disclosed |
| US-4972906-A | Method for selective plugging of a zone in a well | CONOCO INC. (US) | 1990-11-27 | — | — | US | disclosed |
| US-4921047-A | Composition and method for sealing permeable subterranean formations | CONOCO INC. (US) | 1990-05-01 | — | — | US | disclosed |
| US-3977996-A | CHROMIUM (III) CARBOXYLATE, COCATALYST | AEROJET-GENERAL CORPORATION (US) | 1976-08-31 | — | — | US | disclosed |
| US-3978026-A | SYNERGISTIC, CHROMIUMIII TRICARBOXYLATE, COCATALYST | AEROJET-GENERAL CORPORATION (US) | 1976-08-31 | — | — | US | disclosed |
| US-3962182-A | CHROMIUMIII CARBOXYLATE CATALYST | AEROJET-GENERAL CORPORATION (US) | 1976-06-08 | — | — | US | disclosed |
| US-3956241-A | CHROMIUM(III) CHELATE COMPOUND | AEROJET-GENERAL CORPORATION (US) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090041945-A1 | ACTIVE RAY CURABLE COMPOSITION, POLYMERIZATION METHOD, ACTIVE RAY CURABLE INK, IMAGE FORMING METHOD, AND INK-JET RECORDING APPARATUS | RIF1, NAP1L4, NAP1L1 | PPM1B 991/4885PTPN1 2404/4885PPP1CC 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.